Markets · 1 sources covering this

Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion

Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled dominance to establish itself as a leader in other areas and become a major player in infectious diseases. The agreements with Curevo, LimmaTech Biologics and Vaccine Company give Lilly access to novel technology and experimental immunizations for shingles, common bacterial pathogens and Epstein-Barr virus, according to a statement on Tuesday. “These acquisitions reflect …

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·1h ago
Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled dominance to establish itself as a leader in other areas and become a major player in infectious diseases. The agreements with Curevo, LimmaTech Biologics and Vaccine Company give Lilly access to novel technology and experimental immunizations for shingles, common bacterial pathogens and Epstein-Barr virus, according to a statement on Tuesday. “These acquisitions reflect …
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/aa94671a0980f6c4078325f7d631d16ab7178fd7"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion"></iframe>

Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion

How 1 sources are covering this